Signal active
Bio
Roman currently serves as the CEO of Janpix, an oncology-focused start-up. He was formerly an advisor to Index Ventures and, before that, a Principal at Index, where among others he invested in and represented the firm on the boards of GlycoVaxyn (sold to GlaxoSmithKline), Versartis (Nasdaq: VSAR), and Novocure (Nasdaq: NVCR).
He started his career at Boehringer Ingelheim Pharmaceuticals in Connecticut where he was leading development projects in oncology, inflammation and cardiovascular disease, advancing several compounds from pre-clinical to clinical stage.
Roman received a PhD from MIT as well as an MBA from NYU’s Stern School of Business. He has authored or co-authored numerous publications in prestigious journals as well as issued patents.
Location
Boston, Massachusetts, United States, North America
Social
Primary Organization
2013
1-10
Biotechnology, Therapeutics, App Discovery, Oncology
Jobs history
0
N/A
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Roman Fleck is the CEO at Janpix, based in United States, North America. With a background in Biotechnology, Roman Fleck has a rich history of leadership and innovation. Roman Fleck studied MBA unknown @ NYU Stern School of Business. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
0
There is no partner investment available on this profile
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.